Modality
Radioligand
MOA
Anti-Tau
Target
TROP-2
Pathway
Tau
Parkinson'sCervical Ca
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
~Jul 2019
→ ~Oct 2020
Phase 3
Jan 2021
→ Jun 2028
Phase 3Current
NCT07436063
2,541 pts·Parkinson's
2021-01→2028-06·Terminated
NCT03193125
1,190 pts·Cervical Ca
2022-01→2026-08·Completed
3,731 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-104mo awayPh3 Readout· Cervical Ca
2028-06-232.2y awayPh3 Readout· Parkinson's
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Termina…
P3
Complet…
Catalysts
Ph3 Readout
2026-08-10 · 4mo away
Cervical Ca
Ph3 Readout
2028-06-23 · 2.2y away
Parkinson's
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07436063 | Phase 3 | Parkinson's | Terminated | 2541 | UPCR |
| NCT03193125 | Phase 3 | Cervical Ca | Completed | 1190 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |